The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy
Anaïs Hagege, Damien Ambrosetti, Julien Boyer, Alexandre Bozec, J. Doyen, Emmanuel Chamorey, Xingkang He, Isabelle Bourget, Julie Rousset, Esma Saâda, Olivia Rastoin, Julien Parola, Frédéric Luciano, Yihai Cao, Gilles Pagès, Maeva Dufies
Abstract
Targeting Plk1 by onvansertib represents a new strategy for HNSCC patients at the diagnosis in combination with reference treatments, or alone as a second line treatment for HNCSCC patients experiencing relapses.
Topics & Concepts
Head and neck squamous-cell carcinomaCisplatinPLK1Radiation therapyCancer researchMedicineOncologyCancerHead and neck cancerInternal medicineCell cycleChemotherapyMicrotubule and mitosis dynamicsNeuroblastoma Research and TreatmentsCancer-related Molecular Pathways